Personalized genomics, Precision medicine, Manufacture and sales of pharmaceuticals, Development of new drugs, Health-care products
We're tracking Theragen Etex Co's market expansion
How Theragen Etex Co's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
Theragen Etex CoYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Multiple Korean companies reported Q2 2025 financial results, including Kiwoom Securities, SOOP, GS E&C, and others. Several firms announced investments, contracts, and corporate actions.
MedTop and Theragenetex signed a joint sales agreement for the antiemetic drug Prozea Prefilled Injection, containing ramosetron. They aim to expand in the post-operative nausea and vomiting prevention market.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Theragen Etex Co's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
